Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-10
Closed -$21 4102
2022
Q4
$21 Hold
10
﹤0.01% 4116
2022
Q3
$0 Hold
10
﹤0.01% 4076
2022
Q2
$0 Sell
10
-1,984
-99% -$6.99K ﹤0.01% 4093
2022
Q1
$9K Sell
1,994
-3,920
-66% -$21.6K ﹤0.01% 3397
2021
Q4
$48K Buy
5,914
+3,582
+154% +$35.2K ﹤0.01% 2679
2021
Q3
$29K Buy
2,332
+1,130
+94% +$15.7K ﹤0.01% 2926
2021
Q2
$19K Sell
1,202
-652
-35% -$11K ﹤0.01% 3155
2021
Q1
$37K Sell
1,854
-110
-6% -$2.72K ﹤0.01% 2727
2020
Q4
$53K Buy
1,964
+402
+26% +$9.02K ﹤0.01% 2489
2020
Q3
$29K Sell
1,562
-31
-2% -$550 ﹤0.01% 2636
2020
Q2
$29K Buy
1,593
+248
+18% +$3.77K ﹤0.01% 2651
2020
Q1
$12K Sell
1,345
-40
-3% -$597 ﹤0.01% 2959
2019
Q4
$24K Sell
1,385
-439
-24% -$5.86K ﹤0.01% 2808
2019
Q3
$19K Buy
1,824
+1,698
+1,348% +$22.8K ﹤0.01% 2858
2019
Q2
$2K Sell
126
-160
-56% -$2.86K ﹤0.01% 3433
2019
Q1
$5K Buy
+286
New +$5.07K ﹤0.01% 3231
2018
Q3
Sell
-415
Closed -$12K 3626
2018
Q2
$12K Buy
+415
New +$12.4K ﹤0.01% 3083

Other funds holding CLLS

US Bancorp's CLLS Position: Q1 2023 in Review

US Bancorp sold out of Cellectis (CLLS) in Q1 2023, closing a stake of 10 shares — an estimated $21 sold.

US Bancorp first reported a position in CLLS in Q2 2018 and held it in 17 quarters. The position peaked at $53K in Q4 2020. 34 funds tracked by Wall St. Rank hold CLLS as of Q1 2023.

  • US Bancorp reported no remaining Cellectis position as of Q1 2023 after selling out during the quarter.
  • US Bancorp sold 10 Cellectis shares in Q1 2023, an estimated $21.
  • US Bancorp first reported a position in Cellectis in Q2 2018 and held it in 17 quarters.
  • US Bancorp's Cellectis position peaked at $53K in Q4 2020.
  • 34 funds tracked by Wall St. Rank held Cellectis as of Q1 2023.

Based on US Bancorp's 13F filing for Q1 2023, filed 9 May 2023.